Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases
Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases
复制标题
DOI：
10.1007/s002590050017
复制
发表时间：
2000-02-01
期刊：
影响因子：
--
通讯作者：
Biersack, HJ
中科院分区：
文献类型：
--
作者：
Palmedo, H;Guhlke, S;Biersack, HJ
本研究的目的是确定患有骨痛的具有骨转移的前列腺癌患者中Re-188-羟基亚乙基二膦酸盐（HEDP）的最大耐受剂量。22名患者接受单次注射递增剂量的载体添加的Re-188-HEDP [1.3GBq（35 mCi），2.6GBq（70 mCi），3.3 GBq（90 mCi）和4.4 GBq（120 mCi）]。在8周的时间内每周测量血细胞计数和生化参数。认为3级或4级血液学毒性（WHO分级）不可接受。在1.3-GBq组中，在治疗后6个月进行临床随访研究，包括疼痛记录方法（药物，疼痛日记）。未观察到血液学毒性。在剂量为2.6 GBq Re-188-HEDP的患者中首次观察到血液毒性结果。在3.3-GBq组中，1例患者出现1级可逆性血小板减少症，1例患者出现2级可逆性血小板减少症，3例患者出现1级可逆性白细胞减少症。在4.4-GBq组中，在1名和2名患者中观察到3级和4级血小板减少症（基线血小板计数
The aim of this study was to determine the maximum tolerated dose of rhenium-188 hydroxyethylidene diphosphonate (HEDP) in prostate cancer patients with osseous metastases who are suffering from bone pain, Twenty-two patients received a single injection of escalating doses of carrier-added Re-188-HEDP [1.3 GBq (35 mCi), 2.6 GBq (70 mCi), 3.3 GBq (90 mCi) and 4.4 GBq (120 mCi)]. Blood counts and biochemical parameters were measured weekly over a period of 8 weeks. Haematological toxicity (WHO grading) of grade 3 or 4 was considered unacceptable. Clinical follow-up studies including methods of pain documentation (medication, pain diary) were performed for 6 months after treatment, In the 1.3-GBq group. no haematological toxicity was observed. First haematotoxic results were noted in those patients with a dose of 2.6 GBq Re-188-HEDP. In the 3.3-GBq group, one patient showed a reversible thrombopenia of grade 1, one a reversible thrombopenia of grade 2 and three a reversible leukopenia of grade 1. In the 4.4-GBq group, thrombopenia of grades 3 and 4 was observed in one and two patients (baseline thrombocyte count